Reuters logo
9 个月前
BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017
2016年11月21日 / 下午12点52分 / 9 个月前

BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017

Nov 21 (Reuters) - Oragenics Inc :

* Oragenics - expects to file an investigational new drug (ind) update and initiate a phase 2 study with ag013 in united states and europe in early 2017

* Oragenics -a phase 1b clinical trial with ag013 in 25 head,neck cancer patients at high risk for om demonstrated that ag013 was safe and well tolerated

* U.S. FDA grants fast track designation for the development of oragenics' ag013 for oral mucositis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below